153 related articles for article (PubMed ID: 16898075)
1. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. I: conceptual and numerical issues.
Popović J
Eur J Drug Metab Pharmacokinet; 2006; 31(2):79-85. PubMed ID: 16898075
[TBL] [Abstract][Full Text] [Related]
2. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.
Popović J; Mitić R; Sabo A; Mikov M; Jakovljević V; Daković-Svajcer K
Eur J Drug Metab Pharmacokinet; 2006; 31(2):87-96. PubMed ID: 16898076
[TBL] [Abstract][Full Text] [Related]
3. Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.
Popović J
Eur J Drug Metab Pharmacokinet; 2007; 32(1):13-9. PubMed ID: 17479539
[TBL] [Abstract][Full Text] [Related]
4. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride.
Baviskar D; Sharma R; Jain D
Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
6. High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil.
Tsang YC; Pop R; Gordon P; Hems J; Spino M
Pharm Res; 1996 Jun; 13(6):846-50. PubMed ID: 8792420
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bioequivalence of highly variable drugs using Monte Carlo simulations. I. Estimation of rate of absorption for single and multiple dose trials using Cmax.
el-Tahtawy AA; Jackson AJ; Ludden TM
Pharm Res; 1995 Nov; 12(11):1634-41. PubMed ID: 8592662
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
Sawicki W; Janicki S
Int J Pharm; 2002 May; 238(1-2):181-9. PubMed ID: 11996822
[TBL] [Abstract][Full Text] [Related]
9. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
[TBL] [Abstract][Full Text] [Related]
10. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation.
Roth W; Setnik B; Zietsch M; Burst A; Breitenbach J; Sellers E; Brennan D
Int J Pharm; 2009 Feb; 368(1-2):72-5. PubMed ID: 18992310
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of controlled-release calcium antagonists.
Schall R; Müller FR; Müller FO; Luus HG
Clin Pharmacokinet; 1997 Jan; 32(1):75-89. PubMed ID: 9012557
[TBL] [Abstract][Full Text] [Related]
12. Effects of food on the bioequivalence of different verapamil sustained-release formulations.
Waldman SA; Morganroth J
J Clin Pharmacol; 1995 Feb; 35(2):163-9. PubMed ID: 7751427
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability study of two different verapamil formulations.
Horne C; Stenzhorn G; Blume H; Knauf H; Mutschler E
Arch Pharm (Weinheim); 1992 Aug; 325(8):531-6. PubMed ID: 1417461
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
Harder S; Thürmann P; Siewert M; Blume H; Huber T; Rietbrock N
J Cardiovasc Pharmacol; 1991 Feb; 17(2):207-12. PubMed ID: 1709224
[TBL] [Abstract][Full Text] [Related]
15. Tests for individual and population bioequivalence based on generalized p-values.
McNally RJ; Iyer H; Mathew T
Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
[TBL] [Abstract][Full Text] [Related]
16. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
[TBL] [Abstract][Full Text] [Related]
17. Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs.
Yassin AE; Alkhaled F; al-Suwayeh S; Elkheshen S
Boll Chim Farm; 2003 Sep; 142(7):285-9. PubMed ID: 14677272
[TBL] [Abstract][Full Text] [Related]
18. Preparation of floating pellets with verapamil hydrochloride.
Sawicki W; Głód J
Acta Pol Pharm; 2004; 61(3):185-90. PubMed ID: 15481243
[TBL] [Abstract][Full Text] [Related]
19. [Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs].
Chen ZP; Xiao YY; Chen HX; Chen XJ; Li LR; Zhu JB
Yao Xue Xue Bao; 2006 Aug; 41(8):765-71. PubMed ID: 17039785
[TBL] [Abstract][Full Text] [Related]
20. The assessment of individual and population bioequivalence.
Chinchilli VM
J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
